Medtronic (NYSE:MDT) said today that it won CE Mark approval in the European Union for its Visualase brain surgery device.
Fridley, Minn.-based Medtronic said the MRI-guided Visualase system uses a small-diameter probe to deliver laser energy to ablate soft tissue in the brain. It’s been approved in the U.S. since 2007, the company said.
“The introduction of Visualase to European physicians ensures that more patients will have access to this beneficial technology,” brain therapies president Brett Wall said in prepared remarks. “This latest milestone is a testament to our commitment to expanding therapeutic options for physicians and their patients.”